Chai Discovery has been named an AI Pioneer in the 2026 #Disruptors60, unveiled at @TechCrunch Disrupt.
Each year, 60 emerging AI startups are recognized as Disruptors, alongside 15 Pioneers already leading at scale.
We're in great company alongside @AppliedInt, @FireworksAI_HQ, @OpenEvidence and more. Full list ↓
Today, we’re announcing a collaboration with @GSK following its successful evaluation of Chai’s models.
@GSK tested designs from Chai's models in its own wet labs, generated zero-shot with no target-specific training, and found binders to all tested targets.
More ↓
AI in drug discovery isn't just a speed play. It unlocks new therapeutic strategies once out of reach.
At the CDD & AI for Biologics Summit today, Chai’s Ryan Peckner will share how Chai’s latest models can design precise, novel antibodies for hard targets:
https://t.co/yeDxHWUmH1
Announcing Chai × @BMSnews.
BMS has spent decades developing medicines for patients with serious diseases.
Now it will leverage Chai's AI models to support future discoveries, unlocking challenging targets and compressing the timeline from drug concept to candidate.
Tune in to @latentspacepod to hear @Mattmcpartlon1 and @realdealpatil talk about the transformational moment bio AI is going through, and why you don't need a background in biology to make an impact in the space.
Chai Discovery's BioAI Phase Shift: Chai-3, Photoshop for Molecules, One-Shot Drug Design, & Engineering Biology https://t.co/O2XnmMlgY8
@chaidiscovery cofounder @Mattmcpartlon1 and product lead @realdealpatil explain why AI drug design has crossed the threshold from impressive demos to pharma-trusted tools, how Chai-2 and Chai-3 are pushing toward one-shot therapeutic-grade molecules, how Chai’s CAD-like design suite lets scientists precisely engineer antibodies and binding sites, why faster model-to-lab feedback loops could turn pharma’s waterfall discovery process into an iterative loop, and how better models, validation, compute, and infrastructure are turning biology from trial-and-error science into an engineering discipline.
We started Chai with a mission to enable the next generation of breakthrough medicines.
Hear our co-founders @joshim5 and @Mattmcpartlon1 talk to @gradypb on @sequoia's Training Data to talk about the future of AI drug design.
Full episode below.
To date, finding a drug has been a process of guess & check… screening millions of molecules hoping one binds.
@chaidiscovery is changing the paradigm… describe the molecule you want, and the model designs it.
@joshim5 and @Mattmcpartlon1 took antibody hit rates from roughly 1 in 1,000 to 1 in 7. That's the jump from search to engineering.
On this episode of Training Data, they get into where the field actually is, why 2024 was the moment to start, what drug discovery looks like when the computer does the design, and more.
00:00 Introduction
01:52 From Discovery to Design
03:25 Protein AI Breakthroughs Timeline
06:04 Why Start in 2024
10:13 Diffusion Models Intuition
11:41 Building the Avengers Team
15:22 Hit Rates and Scaling Laws
25:01 Molecular CAD Vision
25:24 Faster Design Loops
26:32 Future Drug Discovery
28:37 Platform Business Model
31:14 Partnering Reality Check
33:44 Data Flywheel Explained
37:16 Staying Ahead at Scale
39:44 Culture and What's Next
We’re delighted to announce our third agreement this week, this time a collaboration with @argenxglobal.
argenx has built one of biotechnology’s most productive antibody engines. We’ll be putting Chai’s frontier molecular design platform into the hands of their scientists.
It’s been a landmark few days for Chai Discovery. From announcing our $400M Series C funding round and our collaboration with @Novartis, to working with argenx, the pace towards better drug design is faster than ever.
We’re delighted to announce our collaboration with @Novartis.
Building on a year-long technical engagement, we’re expanding our collaboration with Novartis to support broader deployment of our technology across multiple therapeutic programs.
Novartis will gain access to our latest models for prediction and design, including Chai-3.